TITLE

The real cost of pediatric Crohn’s disease: the role of infliximab in the treatment of pediatric IBD

AUTHOR(S)
Kay, Marsha; Wyllie, Robert
PUB. DATE
April 2003
SOURCE
American Journal of Gastroenterology;Apr2003, Vol. 98 Issue 4, p717
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
No abstract available.
ACCESSION #
9658080

 

Related Articles

  • Infliximab: A Review of its use in the Treatment of Pediatric Crohn's Disease. Broder, Arkady; Rosh, Joel R. // Clinical Medicine Insights: Therapeutics;2010, Issue 2, p235 

    The past decade has brought great change to the treatment of pediatric Crohn's disease. The majority of affected patients now receive therapy directed at the underlying immune dysregulation that is associated with this chronic disease. The monoclonal antibodies directed against tumor necrosis...

  • Differences in phenotype and disease course in adult and paediatric inflammatory bowel disease - a population-based study.  // Inflammatory Bowel Disease Monitor;2012, Vol. 12 Issue 3, p128 

    The article reports on the study that identifies the phenotypic, treatment, and disease course differences betwen adult and pediatric inflammatory bowel disease (IBD) populations. It found no difference in Crohn's disease localization between pediatric and adult-onset patients. It reveals that...

  • Prevalence and correlates of vitamin K deficiency in children with inflammatory bowel disease. Nowak, Jan K.; Grzybowska-Chlebowczyk, Urszula; Landowski, Piotr; Szaflarska-Poplawska, Anna; Klincewicz, Beata; Adamczak, Daria; Banasiewicz, Tomasz; Plawski, Andrzej; Walkowiak, Jaroslaw // Scientific Reports;4/25/2014, p1 

    Although vitamin K deficiency has been implicated in adult inflammatory bowel disease (IBD), its prevalence in pediatric IBD remains unknown. We carried out a cross-sectional study in 63 children with Crohn's disease (CD) and 48 with ulcerative colitis (UC) to assess the prevalence of vitamin K...

  • Complications of infliximab therapy in children and adolescents affected by Crohn's disease. Diamanti, Antonella; Papadatou, Bronislava; Knafelz, Daniela; Gambarara, Manuela; Ferretti, Francesca; Castro, Massimo // American Journal of Gastroenterology;Dec2003, Vol. 98 Issue 12, p2812 

    Presents a letter to the editor about the efficacy of infliximab to induce and maintain the clinical remission in pediatric and adolescent patients affected by Crohn's disease, with a high prevalence of reactions that can induce suspension of a useful treatment.

  • Prolonged Duration of Response to Infliximab in Early But Not Late Pediatric Crohn's Disease. Kugathasan, Subra; Werlin, Steven L.; Martinez, Alfonzo; Rivera, Maria T.; Heikenen, Janice B.; Binion, David G. // American Journal of Gastroenterology;Nov2000, Vol. 95 Issue 11, p3189 

    OBJECTIVES: Tumor necrosis factor-α plays a central role in chronic intestinal inflammation of Crohn's disease. Targeting this cytokine with the chimeric monoclonal antibody infliximab has emerged as an effective form of therapy in adult Crohn's disease patients. We sought to determine...

  • Trends in Early Outpatient Drug Therapy in Pediatric Inflammatory Bowel Disease in Finland: A Nationwide Register-Based Study in 1999-2009. Virta, Lauri J.; Kolho, Kaija-Leena // ISRN Gastroenterology;2012, p1 

    Objective. There are limited data on the changes of treatment strategies of disease-modifying drugs used to treat pediatric inflammatory bowel disease (IBD). Methods. We utilized data from two national registers: the Drug Reimbursement Register for drug costs (for identifying children with IBD)...

  • What Is Inflammatory Bowel Disease.  // Pediatrics for Parents;2001, Vol. 19 Issue 7, p3 

    Describes the inflammatory bowel disease (IBD). Role of Crohn's disease and ulcerative colitis on IBD; Distinction between the diseases of IBC; Treatments for IBD.

  • Intestinal Permeability as a Clinical Surrogate Endpoint in the Development of Future Crohn's Disease Therapies. Han, Xiaonan // Recent Patents on Inflammation & Allergy Drug Discovery;Jun2010, Vol. 4 Issue 2, p159 

    Inflammatory bowel disease (IBD) including Ulcerative colitis (UC) and Crohn's disease (CD) is a major cause of gastrointestinal pathology in children and adolescents. Intestinal hyper-permeability plays a critical role in the etiology of pediatric CD by affecting the penetration of pathogens,...

  • Letter from the editor. Lichtenstein, Gary R. // Gastroenterology & Hepatology;Feb2012, Vol. 8 Issue 2, p80 

    An introduction is presented in which the editor discusses various reports within the issue on topics including the treatment of inflammatory bowel disease (IBD), the use of infliximab in the treatment of Crohn's disease, and the diagnosis and treatment of intestinal Behçet disease.

  • Pediatric Inflammatory Bowel Disease. Antonioli, Donald A. // Pediatric & Developmental Pathology;Jan/Feb2005, Vol. 8 Issue 1, p2 

    Focuses on pediatric inflammatory bowel disease (IBD). Achievement of diagnosis by eliminating known causes of enteritis and colitis; Effects caused by the endoscopic procedure; Effects of colonic cleaning procedures; Histologic features of enteric colitis; Characteristics of pediatric IBD;...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics